Member Info for JOHNO77

Another change of strategy and yet another BETA phase???

Bit dissapointing for holders but they had to do something to adapt to the COVID environment.

I thought it was also all about big data here but now it seems the data is going to be owned by the restaurants or have a got that wrong??

Agreed Draft. Evotec work still all on track. Results due in 5 weeks.

There are only 3 certainties in this life pal. Death, Taxes & CWR..... ;)

Hiya

Oh yes sorry i get what you mean.

they unfortunately hit market during last week in May... Shame our mcap at this price cap is nearer 7 mill as opposed to 4.5ish mill..

Still small fry compared to where it could be soon so hopefully a just minor blip that was required to get the 2mill... All cashed up now which is great.

Nice holding.

50 million?? ?

Traders all gone? Lol.

Next couple of months should be very interesting here so am looking forward to seeing how it all plays out...

P.S good to see you here Digger.

Others may be able to give you more of an insight (or correct me if i am wrong) but they are the main points of the top of my head.

Lots of RNS'es to trawl through if you want more specifics.

Best of luck

The delivery system has very low toxicity and has been proven to degrade naturally within the body. Nuvec itself is not a drug so it does not need to overcome the same regulatory hurdles.

Customers will license our product for their own drugs which will have to have to be be approved in their own right. That will be the responsibility of the client. Many of those hurdles will potentially already be overcome by the time they approach N4.

N4 will gain revenues from the licences straight away so even if the clients drug requires further approval, N4 will already be earning. Once the clients product gets to market the revenues will not only be from licences, they will be from royalties too.

They said they are looking for ways to fast track the in vivo work. They won’t want to start the in vivo unless they have sorted the agglomeration.

Double whammy rns stating agglomeration sorted and in vivo studies commencing would be nice....

Nice 46k buy coming through from Friday.

Was that you having a little top up Leister??? ;))

Best of luck TP. Also had a few top ups myself.

‘In vivo’ not ‘in buck’... lol.

He has been ultra bullish & ramping n4 for yrs. he’s now switched to deramp mode as he’s mega peeved the placees have got in at 4p and he now wants to get in lower than them......

He’s a big cry baby IMO mainly due to the fact he seems overexposed here.

As MayAnya said, all to play for. N4’s in vivo results have always been v good. Results due in approx 6 weeks which should boost the SP. Co also looking at ways to start in buck works earlier (as per last rns) so we could hear news in that at any time.

4p area offers an excellent entry IMO.

This is the buyzone for N4 draft. Difficult to top up though... Tried to buy some when offer was 4p and only offered 10k shares.

Don’t forget in vivo studies also may progress quicker than anticipated. From last covid rns:

“The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target. Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.”

Well this is very annoying, i keep missing my entry here!!! I shouldn't be so greedy haha...

Who knows. Maybe someone just happy to make a smidgen over 10% on their placing stock..?

Happy for them to sell at these levels tbf.

Nice to now have someone from Bosch on the BOD

8/9p target price from Zak Mir on this. Still offering a decent entry at a piddly mcap.

Not surprise to see the early money buying in.

This was 7/8p just after 1st admission, don't think it will take much to get back to those levels and then beyond.